Health · 38 views
Forget GLP-1s—GLP-3s show promise in phase 3 weight loss and diabetes trial
Phase 3 clinical trial results (TRANSCEND-T2D-1) published in The Lancet report that retatrutide, an investigational once-weekly injection for diabetes management, can significantly improve blood sugar levels and lead to substantial…
Summary
Phase 3 clinical trial results (TRANSCEND-T2D-1) published in The Lancet report that retatrutide, an investigational once-weekly injection for diabetes management, can significantly improve blood sugar levels and lead to substantial weight loss in people with Type 2 diabetes.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- Study identifies potential new treatment targets for the most common type of bowel cancerContinue reading
- STAT+: Diabetes association says ‘threat’ preceded members’ ejections, but admits policies were unclearContinue reading
- Infants' Maternal Measles Protection May Not Last Until First MMR DoseContinue reading
- What Did Leaked Data on an mRNA Vaccine Show?Continue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow